Rob Davis, Merck CEO
June 17, 2022 11:26 AM EDTUpdated 12:21 PM
Deals
Pharma

Up­dat­ed: Mer­ck look­ing at Seagen takeover bid in the wake of Clay Sie­gal­l's res­ig­na­tion — re­port

Paul Schloesser

Associate Editor

Mer­ck is eval­u­at­ing a po­ten­tial buy­out of em­bat­tled Seat­tle biotech Seagen, ac­cord­ing to a re­port from the Wall Street Jour­nal on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times